Iovance Biotherapeutics (NASDAQ:IOVA) Given New $18.00 Price Target at Wells Fargo & Company

Iovance Biotherapeutics (NASDAQ:IOVA) had its price target raised by equities researchers at Wells Fargo & Company from $14.00 to $18.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 23.25% from the stock’s current price.

IOVA has been the subject of several other reports. Citizens Jmp boosted their price objective on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. The Goldman Sachs Group started coverage on shares of Iovance Biotherapeutics in a research note on Thursday, September 24th. They issued a “buy” rating and a $15.00 target price on the stock. TD Cowen lifted their target price on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Monday, August 24th. Robert W. Baird set a $6.00 price target on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. Finally, Barclays increased their price target on Iovance Biotherapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ IOVA traded up $0.15 on Wednesday, hitting $14.60. The company’s stock had a trading volume of 7,758,976 shares, compared to its average volume of 15,775,896. Iovance Biotherapeutics has a 12-month low of $1.76 and a 12-month high of $15.30. The stock has a 50 day moving average of $7.79 and a 200-day moving average of $5.27. The company has a market capitalization of $6.62 billion, a price-to-earnings ratio of -19.93 and a beta of 0.83.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business had revenue of $99.31 million for the quarter, compared to analysts’ expectations of $87.83 million. During the same period last year, the company earned ($0.33) earnings per share. The company’s quarterly revenue was up 65.7% on a year-over-year basis. Sell-side analysts expect that Iovance Biotherapeutics will post -0.49 EPS for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

A number of hedge funds have recently made changes to their positions in the company. Sequoia Financial Advisors LLC increased its position in shares of Iovance Biotherapeutics by 5.4% during the second quarter. Sequoia Financial Advisors LLC now owns 32,957 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 1,691 shares during the last quarter. GTS Securities LLC boosted its holdings in Iovance Biotherapeutics by 44.6% in the second quarter. GTS Securities LLC now owns 14,461 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 4,457 shares during the last quarter. Orion Investment Co grew its stake in Iovance Biotherapeutics by 0.3% during the 4th quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock valued at $5,069,000 after purchasing an additional 5,150 shares in the last quarter. Mirador Capital Partners LP grew its stake in Iovance Biotherapeutics by 0.7% during the 2nd quarter. Mirador Capital Partners LP now owns 1,080,288 shares of the biotechnology company’s stock valued at $4,494,000 after purchasing an additional 7,052 shares in the last quarter. Finally, Optiver Holding B.V. increased its holdings in Iovance Biotherapeutics by 24.0% during the 1st quarter. Optiver Holding B.V. now owns 36,660 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 7,092 shares during the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance raised 2026 revenue guidance to $410 million-$420 million, up from $350 million-$370 million previously and above analyst estimates near $402 million. Management cited strong U.S. demand for Amtagvi (lifileucel) and Proleukin, providing the primary catalyst for the stock’s advance. Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
• Positive Sentiment: The outlook increase suggests commercial traction for Iovance’s melanoma treatment portfolio and supports expectations for continued revenue growth. Reports highlighted strong melanoma-drug demand and an anticipated increase of roughly 60% in revenue. Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth
• Positive Sentiment: HC Wainwright raised its price target from $9 to $20 and maintained a Buy rating, implying additional upside based on the referenced $14.45 share price. The higher target reflects greater confidence in Iovance’s commercial turnaround.
• Positive Sentiment: The shares advanced more than 30% on unusually heavy volume and reached their highest level since 2024, indicating that the guidance update attracted substantial market participation. Iovance hits highest since 2024 as analysts cheer guidance raise
• Neutral Sentiment: Despite the stronger revenue outlook, Iovance remains unprofitable, and its valuation now reflects substantial expectations for continued execution.
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revisions may not support further near-term gains. Another analysis argued that much of the turnaround may already be priced in and downgraded the stock to Hold, creating a potential consolidation risk after the sharp rally. Iovance Biotherapeutics Surges: Is This an Indication of Further Gains?

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. Its platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and returned to the patient to help recognize and attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.